CGEM

Cullinan Therapeutics (CGEM) is back in focus after regulators in the U.S. and Australia cleared a global Phase 1b/2a trial of velinotamig in difficult immune thrombocytopenia and warm autoimmune hemolytic anemia.

Cullinan Therapeutics has more than doubled over the past year, which puts a sharp spotlight on whether that move still lines up with the strength of its balance sheet and book value.

The mean of analysts' price targets for Cullinan Therapeutics (CGEM) points to a 129.6% upside in the stock.

Cullinan Therapeutics (NASDAQ:CGEM) outlined upcoming clinical milestones across its immunology and oncology pipeline, including a planned December update for its CD19-directed T-cell engager CLN-978 and data presentations for other programs in November and the fourth quarter.

Cullinan Therapeutics (NasdaqGS:CGEM) plans to report clinical data updates from three T cell engager programs in Q4 2026. The update will include new results for autoimmune and oncology candidates Velinotamig, CLN-978, and CLN-049.

Additional multi-dose data for CLN-978 in difficult-to-treat rheumatoid arthritis (RA), once expected in the third quarter, will now arrive in December.

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) plans to report clinical data from three T cell engager programmes during the fourth quarter of 2026, covering candidates being evaluated in autoimmune diseases and acute myeloid leukaemia.

Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November

Cullinan Therapeutics stock moves after Phase 3 zipalertinib data Cullinan Therapeutics (CGEM) is back in focus after Phase 3 REZILIENT3 trial results showed zipalertinib plus chemotherapy improved progression free survival for EGFR exon 20 insertion non small cell lung cancer patients.

Taiho Pharmaceutical, Taiho Oncology and Cullinan Therapeutics recently reported that the Phase 3 REZILIENT3 trial of investigational EGFR inhibitor zipalertinib plus chemotherapy in previously untreated EGFR exon 20 insertion-positive advanced non-small cell lung cancer met its primary endpoint, delivering a statistically significant 6.0‑month median progression‑free survival improvement over chemotherapy alone with no new safety signals identified.